Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 11/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 11/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1314260 | 0.85 | GABRA2 (0.51) | GABRA2GABRB2KDM4EALDH1A1RAB9A | |
| SCHEMBL31537599 | 0.83 | GABRA2 (0.42) | GABRA2GABRB2KDM4EALDH1A1RAB9A | |
| SCHEMBL15199632 | 0.74 | MEN1 (0.41) | GABRA2GABRB2KDM4EALDH1A1RAB9A | |
| SCHEMBL8403570 | 0.71 | NPSR1 (0.40) | KDM4EALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL31497621 | 0.71 | ADORA2A (0.52) | KDM4EALDH1A1SMN1; SMN2ADORA2AADORA2B | |
| SCHEMBL26001144 | 0.70 | MEN1 (0.40) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL22479152 | 0.70 | KDM4E (0.46) | KDM4EALDH1A1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL15322287 | 0.69 | MAPT (0.40) | GABRA2GABRB2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13181161 | 0.69 | PTGS2 (0.40) | GABRA2GABRB2ADORA2B | |
| SCHEMBL3095507 | 0.69 | PTGS2 (0.39) | GABRA2GABRB2KDM4EALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234352-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234352-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-7696352-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-2114928-A2 | THIOPHENE CARBOXAMIDES AS FACTOR XA INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008086188-A2 | THIOPHENE CARBOXAMIDES AS FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008086188-A2 | THIOPHENE CARBOXAMIDES AS FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20070185092-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070185092-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070185092-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185092-A1 | FACTOR Xa INHIBITORS | TFPI, F12, F11 | GABRA2 3275/4885GABRB2 3348/4885KDM4E 2399/4885 |
| US-20100234352-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | GABRA2 3275/4885GABRB2 3348/4885KDM4E 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.